Claims
- 1. A pharmaceutical formulation comprising halofantrine free base in association with a pharmaceutically acceptable carrier in a form suitable for oral administration in which the formulation is a self-emulsifying formulation.
- 2. A formulation according to claim 1 comprising halofantrine free base, a medium/long chain triglyceride lipid, a medium/long chain mono/diglyceride lipid and a surfactant.
- 3. A pharmaceutical formulation according to claim 2 in which the medium chain trigyceride lipid is a triglyceride of a C.sub.8-10 fatty acid; the medium chain mono/diglyceride is a mono/diglyceride of caprylic or capric acid; and the surfactant is polyoxyethyelene 20 sorbitan monoleate.
- 4. A pharmaceutical formulation according to claim 2 in which the long chain triglyceride lipid is peanut oil, the long chain mono/diglyceride is a mono/diglyceride of a long chain fatty acid from maize oil, and the surfactant is polyoxyethyelene 20 sorbitan monoleate.
- 5. A formulation according to claim 1 in which the formulation is a semi-solid/solid formulation which either disperses or forms a microemulsion/micellar system upon contact with aqueous environment.
- 6. A pharmaceutical formulation according to claim 5 in which the matrix used to prepare the semi solid/solid formulation is selected from polyethylene glycol 6000, a hydrogentated food-grade oil containing C.sub.8-18 glycerides or C.sub.8-18 ethoxylated fatty acids, and d-.alpha.-tocopheryl polyethylene glycol 100 succinate and combinations thereof.
- 7. A formulation according to claim 6 further comprising an ingredient selected from the group consisting of a surfactant/dispersant, silicon dioxide, a filler, a disintegrant, and an excipient, wherein the ingredient is used to modify the rate of drug release from the formulation.
- 8. A pharmaceutical formulation comprising halofantrine free base and a pharmaceutically acceptable carrier in a form suitable for intravenous administration.
Priority Claims (2)
Number |
Date |
Country |
Kind |
9406858 |
Apr 1994 |
GBX |
|
9416404 |
Aug 1994 |
GBX |
|
Parent Case Info
This is a continuation of application Ser. No. 08/718,343, filed Oct. 4, 1996 and abandoned on Oct. 16, 1997 which was also a 371 of PCT/EP95/01257, filed Apr. 4, 1995.
US Referenced Citations (3)
Foreign Referenced Citations (1)
Number |
Date |
Country |
WO 9301809 |
Feb 1993 |
GBX |
Non-Patent Literature Citations (2)
Entry |
Nothdurft et al., "Halofantrine: a new substance for treatment of multidrug-resistant malaria", Clincal Investig, 71:69-73, (1993). |
Shah et al., "Self-emulsifying drug delivery systems (SEDDS) for improving in vitro dissolution and oral absorption of lipophilic drugs", Bull. Tech/Gattefosse Rep., vol. 85, pp. 45-54, 1993. |
Continuations (1)
|
Number |
Date |
Country |
Parent |
718343 |
|
|